Alpha Cognition (NASDAQ:ACOG) Stock Rating Upgraded by B. Riley Financial

Alpha Cognition (NASDAQ:ACOG) was upgraded by investment analysts at B. Riley Financial to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other research firms have also recently weighed in on ACOG. Maxim Group initiated coverage on shares of Alpha Cognition in a report on Friday, May 29th. They issued a “buy” rating and a $12.00 price objective on the stock. Raymond James Financial assumed coverage on shares of Alpha Cognition in a research note on Friday, July 10th. They set an “outperform” rating and a $20.00 target price for the company. Craig Hallum restated a “buy” rating and issued a $17.00 target price on shares of Alpha Cognition in a research report on Friday, August 14th. HC Wainwright upped their target price on shares of Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Wall Street Zen upgraded shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

Alpha Cognition Price Performance

Shares of NASDAQ ACOG opened at $9.50 on Wednesday. Alpha Cognition has a 1-year low of $4.50 and a 1-year high of $10.00. The business’s fifty day moving average price is $7.98 and its two-hundred day moving average price is $6.63. The firm has a market capitalization of $206.91 million, a PE ratio of -8.64 and a beta of 2.31.

Alpha Cognition (NASDAQ:ACOG) last posted its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. The company had revenue of $6.00 million during the quarter, compared to the consensus estimate of $4.38 million. Equities research analysts expect that Alpha Cognition will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Cognition

Several large investors have recently bought and sold shares of the stock. Opaleye Management Inc. raised its position in shares of Alpha Cognition by 1,698.5% during the 4th quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock worth $13,460,000 after buying an additional 1,955,642 shares in the last quarter. AWM Investment Company Inc. bought a new position in shares of Alpha Cognition in the second quarter valued at approximately $12,073,000. Ikarian Capital LLC boosted its holdings in shares of Alpha Cognition by 11.6% in the fourth quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock valued at $6,866,000 after acquiring an additional 110,000 shares in the last quarter. Cable Car Capital LP increased its stake in shares of Alpha Cognition by 68.8% during the second quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock valued at $8,108,000 after acquiring an additional 354,278 shares during the period. Finally, Sphera Funds Management LTD. increased its stake in shares of Alpha Cognition by 67.6% during the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock valued at $3,690,000 after acquiring an additional 228,864 shares during the period.

Trending Headlines about Alpha Cognition

Here are the key news stories impacting Alpha Cognition this week:

• Positive Sentiment: B. Riley initiated coverage with a Buy rating, highlighting Alpha Cognition’s Alzheimer’s drug opportunity. The new coverage adds to the bullish analyst narrative and supports investor optimism. Alpha Cognition rises as B. Riley initiates at Buy on Alzheimer’s drug
• Positive Sentiment: HC Wainwright raised its fourth-quarter 2026 EPS estimate, providing a potentially supportive near-term signal. The firm continues to rate ACOG Buy with a $20 price target, materially above recent trading levels. Alpha Cognition Q4 EPS Estimate Increased by HC Wainwright
• Positive Sentiment: HC Wainwright modestly improved its first-quarter 2027 EPS forecast to a loss of $0.12 from a loss of $0.19 and raised its full-year 2027 estimate to a loss of $0.31 from a loss of $0.32. These revisions suggest expectations for improving results beyond 2026.
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $20 price target, but its estimates still anticipate continuing losses, including a projected $1.33-per-share loss for fiscal 2026 and a $0.31-per-share loss for fiscal 2027.
• Negative Sentiment: The firm lowered several forecasts, including Q3 2026 EPS to a loss of $0.33 from $0.20, Q4 2026 EPS to a loss of $0.25 from $0.20, fiscal 2026 EPS to a loss of $1.33 from $1.08, and Q2 2027 EPS to a loss of $0.13 from $0.10. These cuts underscore ongoing commercialization and profitability risks.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.